The investor frenzy over oral hepatitis C drugs is raging this morning. Inhibitex ($INHX), a small Georgia-based developer, has doubled in value today with its top-line data from a mid-stage trial of its oral nucleotide polymerase inhibitor INX-189, which offers another promising treatment of the liver-damaging virus that doesn't require injections of interferon.
The company's data are sure to be a hot topic of discussion at the American Association for the Study of Liver Diseases meeting in San Francisco. The firm today provided data from a Phase II trial of its INX-189 that tests the treatment as a standalone drug and in combination with the antiviral ribavirin. In the first group that took INX-189 over 7 days, there was "potent and dose-dependent antiviral activity with a median HCV RNA reduction from baseline of -4.25 log10 IU/mL. Further, 200 mg INX-189 was generally well tolerated, and there were no serious adverse events (SAE) or dose dependent adverse events (AE) observed," the company said. Those data are comparable to what Pharmasset ($VRUS) showed from an earlier study of its similar oral drug PSI-7977, which is in late-stage development, TheStreet reports.
Read more:
0 comments:
Post a Comment